Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 3Completed 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Genitourinary 1

Conditions

Glioblastoma 2Gliosarcoma 1Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × vitespin × Clear all
NCT03018288 2025-08-08

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
90 enrolled 24 charts
CNS

Glioblastoma, Glioma

NCT01814813 2025-01-24

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
90 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01147536 2021-06-03

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Agenus Inc.

Phase 2 Terminated
12 enrolled 5 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡